Write your message
Volume 4, Issue 1 (6-2014)                   cmja 2014, 4(1): 745-756 | Back to browse issues page

XML Persian Abstract Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Farazi A, Zarrinfar N, Sarmadian H, Jabbariasl M, Mirzajani P. Comparison of Garlic and Rifampin Consumption in Treatment and Recurrence of Brucellosis. cmja 2014; 4 (1) :745-756
URL: http://cmja.arakmu.ac.ir/article-1-226-en.html
1- Arak University of Medical Sciences , farazialiasghar@yahoo.com
2- Arak University of Medical Sciences
Abstract:   (93236 Views)

  Introduction: : Due to the importance of Rifampin on Tuberculosis treatment and the high prevalence of brucellosis and tuberculosis in Iran, it is necessary to replace Rifampin in brucellosis treatment with other drugs that are better tolerated and have fewer side effects.

  Methods: This research is a double-blinded clinical trial in which 36 patients were in group 1 prescribed by doxycycline capsule and garlic tablet for 8 weeks plus gentamicin for one week and 36 patients were enrolled as group 2 being prescribed by doxycycline and rifampin for 8 weeks plus gentamicin for one week. The data were collected and analyzed by SPSS version18.

  Result: The mean age was 40.2±17.1 in group 1 and 40.1±15.9 in group 2. Treatment failore was 8.8% in group 1 and 7.8% in group 2. There was no significant difference in rate between two groups (P=0.62). The disease recurrence after 9 months was 14.7% in group 1 and 8.6% in group 2 (p=0.42).

  Conclusion: Due to the same effect of garlic and Rifampin in this study and in order to prevent rifampin resistance in tuberculosis patients and its less side effects, it is recommended to replace garlic as an alternative drug in brucellosis treatment.

  

 

Full-Text [PDF 2020 kb]   (18901 Downloads)    
Type of Study: Research |

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 CC BY-NC 4.0 | Complementary Medicine Journal

Designed & Developed by : Yektaweb